Sir:
====

We are well into the era of solid organ transplantation for the preservation of life. Now, with a paradigm shift, we are entering an era of transplantation of parts not necessarily essential for physical survival. As we consider transplants designed to improve quality of life, we must address the elephant in the room for vascularized composite allograft, *the cost of immunosuppression*.

RENAL FAILURE
=============

The 5-year incidence of chronic renal failure for nonrenal transplants varies based on the type of transplant performed. The values range from 7% for heart--lung transplants to 21% for intestinal transplants.^[@R1]^ Among these groups, end-stage renal disease occurred at a rate of 1% to 1.5% per year.^[@R1]^ These rates and need for renal replacement therapy will likely continue to increase, given the longevity of the population of nonrenal transplant recipients.

DIABETES MELLITUS
=================

Immunosuppressive medications account for up to 74% of new onset of diabetes after transplantation (NODAT).^[@R2]^ One study found the cumulative incidence of NODAT to be 9%, 16%, and 24% at 3, 12, and 36 months, respectively.^[@R2]^ Other meta-analyses report the incidence of NODAT to range from 2% to 50% in the first year after the transplant.^[@R3]^

Both steroids and calcineurin inhibitors have been associated with glucose metabolism impairment.^[@R2]^ Studies have reported that in the initial years after a transplant, the incidence of NODAT associated with higher doses of corticosteroids was as high as 46%.^[@R2]^

CANCER
======

A recent NIH study in 2011 evaluated over 175,000 transplant patients and reported a 2-fold increase in the risk of cancer development among all U.S. transplant recipients.^[@R4]^ The most common cancers among transplant recipients were non-Hodgkin's lymphoma (14.1%), lung cancer (12.6%), liver cancer (8.7%), and kidney cancer (7.1%).^[@R4]^

Another type of cancer found among transplant recipients is skin cancer. A study in the Netherlands reviewed incidence of skin cancer in 764 renal transplant patients between 1966 and 1988. They found that the overall risk of developing the first tumor increased from 10% after 10 years to 40% after 20 years of graft survival.^[@R5]^

SUMMARY
=======

As we entertain increased use of vascularized composite allograft in treating our patients, we must be prepared for frank discussions regarding the risk of transplanting non--life-saving body parts requiring full immunosuppression. Today, a transplant patient will likely receive a calcineurin inhibitor, cyclosporine, or tacrolimus. Steroids are still commonly used in most centers. Mycophenolate mofetil has replaced azathioprine, with considerable benefit to patients. In some centers, single-drug immunosuppression suffices for many kidney and liver patients. The majority of centers, however, commit patients to triple-drug immunosuppression with prednisone, mycophenolate mofetil, and cyclosporine or tacrolimus. Although chronic immune-suppressive therapy ensures prevention of organ rejection, these medications place recipients at an increased risk for developing chronic renal failure, diabetes mellitus, and certain types of cancers. As clinicians, we should discuss not only the transplant process but also the long-term risks and complications of such an operation.
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